Clinical Trial Update: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Clinical trial update indicates a Phase 1 dose-escalation and dose-expansion study of CPO-100 in patients with advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• CPO-100

Snippet

Sponsor: Conjupro Biotherapeutics, Inc. | Conditions: Solid Tumor | Phase 1 | Status: TERMINATED